VSJ-110
VP-VSJ-110-2101
Phase 2 small_molecule completed
Quick answer
VSJ-110 for Allergic Conjunctivitis is a Phase 2 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vanda Pharmaceuticals
- Indication
- Allergic Conjunctivitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed